Novavax (NVAX) Expands Large-Scale Global Manufacturing Capacity, Acquires Praha Vaccines in Czech Republic for $167 million

Novavax Expands Large-Scale Global Manufacturing Capacity

Novavax acquires Praha Vaccines in Czech RepublicAnnual operating capacity of over 1 billion doses of COVID-19 vaccine antigen

GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million. The acquisition includes a biologics manufacturing facility and associated assets in Bohumil, Czech Republic. The facility is... More